Asset Details
Do you wish to reserve the book?
Authorized Generics In The US: Prevalence, Characteristics, And Timing, 2010–19
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Authorized Generics In The US: Prevalence, Characteristics, And Timing, 2010–19
Do you wish to request the book?
Authorized Generics In The US: Prevalence, Characteristics, And Timing, 2010–19
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Authorized Generics In The US: Prevalence, Characteristics, And Timing, 2010–19
2023
Overview
Authorized generics are approved brand-name drugs that are sold by brand-name manufacturers or licensees without brands on their labeling. Despite their prevalence in prescription drug markets in the US, little is known about trends in their launches, their timing relative to traditional generics, and the characteristics of their respective brandname drugs. We linked Food and Drug Administration and IQVIA data to investigate newly launched authorized generics during the period 201019. We found 854 launches over this period, with launches peaking in 2014. Marketing appears strategic: In markets with traditional generics, three-fourths of authorized generics launched after the respective generic competition started. When we focused on markets where generics were eligible for the 180-day exclusivity, about 70 percent of authorized generics launched before or during the exclusivity period. These findings provide insights for future research on the effect of authorized generics on competition, prices, and access to generics.
